• Теги
    • избранные теги
    • Компании1492
      • Показать ещё
      Разное399
      • Показать ещё
      Страны / Регионы313
      • Показать ещё
      Люди101
      • Показать ещё
      Международные организации18
      • Показать ещё
      Издания57
      • Показать ещё
      Формат34
      Показатели33
      • Показать ещё
Выбор редакции
24 марта, 17:54

Teva Pharma Denies Rumors of Global Workforce Reduction

According to recent reports, Teva Pharmaceutical Industries Ltd (TEVA) is likely lay off almost 11% of its global workforce to cut costs and improve growth prospects.

Выбор редакции
24 марта, 03:06

Mylan Recalls 81,000 EpiPens Outside U.S. After Reports Of Failure

function onPlayerReadyVidible(e){'undefined'!=typeof HPTrack&&HPTrack.Vid.Vidible_track(e)}!function(e,i){if(e.vdb_Player){if('object'==typeof commercial_video){var a='',o='m.fwsitesection='+commercial_video.site_and_category;if(a+=o,commercial_video['package']){var c='&m.fwkeyvalues=sponsorship%3D'+commercial_video['package'];a+=c}e.setAttribute('vdb_params',a)}i(e.vdb_Player)}else{var t=arguments.callee;setTimeout(function(){t(e,i)},0)}}(document.getElementById('vidible_1'),onPlayerReadyVidible); Generic drugmaker Mylan NV has recalled about 81,000 EpiPen devices in countries outside the United States, following two reports of the life-saving allergy shot failing to work in emergencies. In both situations, patients were able to obtain treatment through the use of an alternate EpiPen, Mylan said on Wednesday. The recall affects devices distributed in Australia, New Zealand, Europe and Japan only, according to the company. Mylan said it is working with the regulatory authorities, where appropriate, to inform them about the recall. The U.S. drugmaker, which is the focus of multiple federal investigations, has come under fire for staggering price increases on the emergency shot in the United States. Mylan has also been heavily criticized for classifying EpiPen as a generic rather than a branded product, which led to much smaller rebates from the company to state Medicaid programs. (Reporting by Natalie Grover in Bengaluru; Editing by Sai Sachin Ravikumar and Shounak Dasgupta) -- This feed and its contents are the property of The Huffington Post, and use is subject to our terms. It may be used for personal consumption, but may not be distributed on a website.

Выбор редакции
21 марта, 23:22

Mylan Receives Tentative Approval from FDA for HIV Therapy

Mylan N.V. (MYL) obtained a tentative approval from the FDA under the U.S. President's Emergency Plan for AIDS Relief (PEPFAR) for the New Drug Application for cocktail therapy Sustiva, lamivudine and Viread, 400 mg/300 mg/300 mg (TLE400).

21 марта, 16:30

Is Mylan N.V. (MYL) a Great Stock for Value Investors?

Is Mylan N.V. a great pick from the value investor's perspective right now? Read on to know more.

Выбор редакции
17 марта, 16:27

Pharma Stock Roundup: AstraZeneca's Lynparza Impresses in Study, Merck Drug Label Expanded

Regulatory and pipeline updates from companies like AstraZeneca (AZN) and Merck were in focus this week.

Выбор редакции
13 марта, 16:40

Acorda's Four Ampyra Patents Upheld by PTAB, Shares Rise

U.S. Patent and Trademark Office (USPTO) Patent Trials and Appeal Board (PTAB) upheld four patents of Acorda's key growth driver, Ampyra.

09 марта, 18:53

Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed

Sucampo Pharmaceuticals, Inc. (SCMP) reported adjusted earnings of 68 cents per share in the fourth quarter of 2016, beating the Zacks Consensus Estimate of 49 cents by 38.8%.

08 марта, 17:30

J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day

J2 Global, eHealth, Pfizer, Amgen and Mylan highlighted as Zacks Bull and Bear of the Day

07 марта, 23:50

Trump's Tweet Hits Pharma Stocks, Promises Decreased Drug Prices

A President Donald Trump tweet promising to increase competition and decrease prices in the drug industry sent pharmaceutical stocks falling on Tuesday.

06 марта, 17:30

The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

The Zacks Analyst Blog Highlights: Mylan, Roche, AstraZeneca, Merck and Sanofi

Выбор редакции
03 марта, 16:33

Pharma Stock Roundup: Mylan, Endo Report 4Q Results, FDA Nod for AZN Diabetes Drug

Quite a few companies including AstraZeneca (AZN) provided pipeline/regulatory updates this week.

03 марта, 00:46

Mylan (MYL) Beats on Q4 Earnings, Stock Up on Strong View

Shares of Mylan N.V.'s (MYL) were up 7.2% after the company beat expectations in the fourth-quarter 2016 and provided a strong outlook for 2017 amid challenging conditions.

02 марта, 14:57

Mylan stock price target raised to $48 from $44 at RBC Capital

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

Выбор редакции
01 марта, 15:52

Mylan's stock soars 7.5% premarket after Q4 results

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news.

28 февраля, 17:39

Theravance (TBPH) Q4 Loss Wider than Expected, Revenues Beat

Theravance Biopharma, Inc. (TBPH) reported fourth-quarter 2016 loss of $1.36 per share, much wider than both the Zacks Consensus Estimate of a loss of $1.07 and the year-ago loss of $1.23.